Literature DB >> 9814944

Lessons for AIDS vaccine development from non-AIDS vaccines.

M L Clements-Mann1.   

Abstract

Critical misconceptions about vaccine development have arisen in the context of acquired immunodeficiency syndrome (AIDS) vaccine research. These include: the goal of vaccination; the biological relevance and predictive value of animal models; the meaning of "correlates of protective immunity"; the nature and duration of vaccine-induced immune responses; and the need for multiple, iterative field trials. In this article, lessons from the history of successful vaccine development relevant to these issues are discussed. Clarity about these central issues and adherence to a common vocabulary are important for the process of establishing an appropriate, milestone-driven process for developing safe, effective AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814944

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Causal Vaccine Effects on Binary Postinfection Outcomes.

Authors:  Michael G Hudgens; M Elizabeth Halloran
Journal:  J Am Stat Assoc       Date:  2006-03       Impact factor: 5.033

2.  Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.

Authors:  Peter B Gilbert; Ying Huang
Journal:  Epidemiol Methods       Date:  2016-01-23

3.  In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.

Authors:  Holly Janes; Peter Gilbert; Susan Buchbinder; James Kublin; Magdalena E Sobieszczyk; Scott M Hammer
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-25       Impact factor: 2.205

4.  A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomes.

Authors:  Jincheng Zhou; Haitao Chu; Michael G Hudgens; M Elizabeth Halloran
Journal:  Stat Med       Date:  2015-07-20       Impact factor: 2.373

Review 5.  New clinical trial designs for HIV vaccine evaluation.

Authors:  Zoe Moodie; Holly Janes; Yunda Huang
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

6.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

7.  Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.

Authors:  Peter B Gilbert; Erin E Gabriel; Xiaopeng Miao; Xiaoming Li; Shu-Chih Su; Janie Parrino; Ivan S F Chan
Journal:  J Infect Dis       Date:  2014-05-13       Impact factor: 5.226

Review 8.  The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.

Authors:  Jonaid Ahmad Malik; Sakeel Ahmed; Aroosa Mir; Mrunal Shinde; Onur Bender; Farhan Alshammari; Mukhtar Ansari; Sirajudheen Anwar
Journal:  J Infect Public Health       Date:  2022-01-05       Impact factor: 3.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.